Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application

Cardiology (Switzerland)

Volumn 122, Issue 2, 2012, Pages 104-112

  Wachter, S Blake ^a   Gilbert, Edward M ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Adrenergic receptors; Blockers; G protein

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; DICHLORISOPRENALINE; GUANINE NUCLEOTIDE; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PROPRANOLOL; TIMOLOL; VASODILATOR AGENT; XAMOTEROL;

ANGINA PECTORIS; CONGESTIVE CARDIOMYOPATHY; DRESSLER SYNDROME; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; INVERSE AGONISM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; GTP-BINDING PROTEINS; HEART FAILURE; HISTORY, 20TH CENTURY; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84863096615     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000339271     Document Type: Review

References (58)

1. Bristow MR, Ginsburg R, Umans V, et al: Beta 1-and beta 2-adrenergic-receptor sub-populations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59: 297-309.
2. Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R: Beta1-and beta 2-ad-renergic receptor-mediated adenylate cy-clase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989; 35: 295-303.
3. Cohn JN, Levine TB, Olivari MT, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984; 311: 819-823.
4. Langley JN: Preliminary notice of experiments on the physiological action of jaboran-di. Br Med J 1875; 1: 241-242.
5. Maehle AH: 'Receptive substances': John Newport Langley (1852-1925) and his path to a receptor theory of drug action. Med Hist 2004; 48: 153-174.
6. Limbird LE: The receptor concept: a continuing evolution. Mol Interv 2004; 4:326-336.
7. von Euler US: Hormones of the sympathetic nervous system and the adrenal medulla. Br Med J 1951; 1:105-108.
8. Ahlquist RP: A study of the adrenotropic receptors. Am J Physiol 1948; 153: 586-600.
9. Frishman WH: Fifty years of beta-adrener-gic blockade: a golden era in clinical medicine and molecular pharmacology. Am J Med 2008; 121: 933-934.
10. Bylund DB: Alpha-and beta-adrenergic receptors: Ahlquist's landmark hy pot hesis of a single mediator with two receptors. Am J Physiol Endocrinol Metab 2007; 293:E1479-1481.
11. Stapleton MP: Sir James Black and proprano-lol: the role of the basic sciences in the history of cardiovascular pharmacology. Tex Heart Inst J 1997; 24:336-342.
12. Goldstein S: The beta blocker heart attack trial: at last, an effective medical therapy to prevent death from coronary heart disease. Henry Ford Hosp Med J 1982; 30:173-174.
13. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I: Effect of chronic beta-adrener-gic receptor blockade in congestive cardio-myopat hy. Br Heart J 1975; 37: 1022-1036.
14. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, Kobilka BK: Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci USA 1987; 84: 7920-7924.
15. Kobilka BK, Dixon RA, Frielle T, et al: cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84:46-50.
16. Emorine LJ, Marullo S, Briend-Sutren MM, et al: Molecular characterization of the human beta 3-adrenergic receptor. Science 1989; 245:1118-1121.
17. Gauthier C, Tavernier G, Charpentier F, Langin D, LeMarec H: Functional beta 3-ad-renoceptor in the human heart. J Clin Invest 1996; 98:556-562.
18. Bristow MR, Anderson FL, Port JD, et al: Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84:1024-1039.
19. Bristow MR, Hershberger RE, Port JD, et al: Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82:I12-25.
20. White M, Roden R, Minobe W, et al: Age-related changes in beta-adrenergic neuroef-fector systems in the human heart. Circulation 1994; 90:1225-1238.
21. Drazner MH, Peppel KC, Dyer S, Grant AO, Koch WJ, Lefkowitz RJ: Potentiation of beta-adrenergic signaling by adenoviral-mediat-ed gene transfer in adult rabbit ventricular myocytes. J Clin Invest 1997; 99: 288-296.
22. Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein k inase A. Nature 1997; 390: 88-91.
23. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ: Altered expression of beta-adren-ergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87:454-463.
24. Levy FO, Zhu X, Kaumann AJ, Birnbaumer L: Efficacy of beta 1-adrenergic receptors is lower than that of beta 2-adrenergic receptors. Proc Natl Acad Sci USA 1993; 90:10798-10802.
25. Colledge M, Scott JD: AKAPs: from structure to function. Trends Cell Biol 1999; 9: 216-221.
26. Zhou YY, Cheng H, Bogdanov KY, et al: Localized cAMP-dependent signaling mediates beta 2-adrenerg ic modu lat ion of ca rd iac excitation-contraction coupling. Am J Physi-ol 1997; 273:H1611-1618.
27. Bogoyevitch MA, Andersson MB, Gillespie-Brown J, et al: Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J 1996; 314: 115-121.
28. Luttrell LM, Ferguson SS, Daaka Y, et al: Be-ta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283:655-661.
29. Williams NG, Zhong H, Minneman KP: Differential coupling of alpha1-, alpha2-, and beta-adrenergic receptors to mitogen-acti-vated protein kinase pathways and differentiation in transfected PC12 cells. J Biol Chem 1998; 273: 24624-24632.
30. Steinberg SF: The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 1999; 85: 1101-1111.
31. Communal C, Singh K, Sawyer DB, Colucci WS: Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210-2212.
32. Milano CA, Allen LF, Rockman HA, et al: Enhanced myocardial function in transgen-ic mice overexpressing the beta 2-adrenergic receptor. Science 1994; 264: 582-586.
33. Koch WJ, Rockman HA, Samama P, et al: Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995; 268: 1350-1353.
34. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al: Myocardial-directed overexpres-sion of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32:817-830.
35. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96:7059-7064.
36. Iwase M, Uechi M, Vatner DE, et al: Cardio-myopathy induced by cardiac Gs alpha over-expression. Am J Physiol 1997; 272:H585-589.
37. Asai K, Yang GP, Geng YJ, et al: Beta-adren-ergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest 1999; 104:551-558.
38. Joseph J, Gilbert EM: The sympathetic nervous system in chronic heart failure. Prog Cardiovasc Dis 1998; 41: 9-16.
39. Bristow MR, Ginsburg R, Minobe W, et al: Decreased catecholamine sensitivity and be-ta-adrenergic-receptor density in failing human hearts. New Engl J Med 1982; 307: 205-211.
40. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the beta-ad-renergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986; 74: 1290-1302.
41. White M, Yanowitz F, Gilbert EM, et al: Role of beta-adrenergic receptor downregulation in t he pea k exercise response in pat ients with heart failure due to idiopathic dilated cardio-myopathy. Am J Cardiol 1995; 76:1271-1276.
42. Mann DL, Kent RL, Parsons B, Cooper GT: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992; 85: 790-804.
43. Bristow MR, Larrabee P, Minobe W, et al: Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992; 19(suppl 1):S68-80.
44. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH Jr: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101:122-124.
45. Talwar KK, Bhargava B, Upasani PT, Verma S, Kamlakar T, Chopra P: Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomy-opathy. J Card Fail 1996; 2: 273-277.
46. Lombardi WL, Gilbert EM: Carvedilol in the failing heart. Clin Cardiol 2001; 24: 757-766.
47. Packer M, Bristow MR, Cohn JN, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. New Engl J Med 1996; 334:1349-1355.
48. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
50. Packer M, Coats AJ, Fowler MB, et al: Effect of carvedilol on survival in severe chronic heart fa ilure. New Engl J Med 2001; 344: 1651-1658.
51. MacGregor JF, Wachter SB, Munger M, Stod-dard G, Bristow MR, Gilbert EM: Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail 2009; 15:5-8.
52. Waagstein F, Bristow MR, Swedberg K, et al: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342:1441-1446.
53. Wikstrand J, Hjalmarson A, Waagstein F, et al: Dose of metoprolol CR/XL and clinical outcomes in patients w it h heart fai lure: a nal-ysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Car-diol 2002; 40:491-498.
54. Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
55. Wollert KC, Drexler H: Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world? Circulation 2002; 106:2164-2166.
56. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
57. Poole-Wilson PA, Swedberg K, Cleland JG, et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metopro-lol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
58. Flather MD, Shibata MC, Coats AJ, et al: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.